Posts Tagged ‘healthcare’

Vital Images Inc. (VTAL) soars on hookup with Japanese giant

Thursday, April 28th, 2011

Vital Images Inc. (Nasdaq: VTAL) shares rallied 31.5% to $18.65 in morning trading Thursday, after Toshiba Medical Systems Co. said late Wednesday that it would acquire the provider of image-visualization software to the medical industry for $273 million. Volume for the stock was 3.7 million shares, overwhelming a daily average of 52,000.

Under the terms of the agreement, which has been unanimously approved by each of Vital Images’ and TMSC’s boards of directors, Vital Images’ shareholders will receive $18.75 in cash for each outstanding share of Vital Images common stock they own. This represents a 39% premium over the volume-weighted average Vital Images share price for the past 30 days.

Toshiba Medical Systems Co. CEO Satoshi Tsunakawa commented, “After a decade-long successful partnership spanning more than 50 countries, TMSC is taking the partnership to the next level. We have enormous respect for Vital Images’ products, pipeline and people, and look forward to working with their highly skilled team to enhance clinical value for patients throughout the world.”

Chief Executive Officer of Vital Images, Michael Carrel also commented on the developments, “TMSC has been our largest customer for a decade, as well as a strategic development partner. We will combine forces to enhance the multi-modality platform we have been marketing to hospitals in the U.S. and overseas. This transaction means we can now accelerate our global presence with the strength and backing of TMSC.”

Minneapolis-based Vital Images, Inc. is a leading provider of advanced visualization and analysis software for physicians and healthcare specialists.

Chelsea Therapeutics (CHTP) stocks soar on new drug application

Monday, April 18th, 2011

Chelsea Therapeutics International Ltd. (Nasdaq: CHTP) shares rose 24.4% Monday after the biotechnology company said it would file a new application for its hypotension treatment in the third quarter. The Charlotte-based company traded in 3.1 million shares, which sold for $4.95, or 97 cents better than Friday’s close.

The Company reaffirmed its NORTHERA™ (droxidopa) new drug application (NDA) filing strategy following correspondence with the U.S. Food and Drug Administration (FDA) regarding recent data from Northera Study 306A and protocol amendments to ongoing Northera Study 306B, comparing the rate of patient reported falls associated with symptomatic neurogenic orthostatic hypotension (NOH) in patients with Parkinson’s disease (PD) taking Northera versus placebo.

According to Chelsea President and CEO Dr. Simon Pedder, “We believe the remarkable safety and tolerability of Northera coupled with the robust clinical benefit demonstrated throughout our Phase III program provide a strong basis for the approval of Northera as a novel treatment for symptomatic neurogenic orthostatic hypotension.”

Pedder continued, “We continue to be appreciative of the guidance that the FDA has provided to Chelsea as we prepare to file this new NDA in the third quarter of 2011. Following the approval of Northera, we look forward to building on the clinical work currently underway in Study 306B and completing the necessary studies to allow for a post-marketing expansion of the label including a claim that Northera reduces falls in neurogenic orthostatic hypotension from Parkinson’s Disease.”

Chelsea is a biopharmaceutical development company that acquires and develops innovative products for the treatment of a variety of human diseases.

Amarin Corporation (AMRN) skyrockets on promising results from fish oil drug candidate

Monday, April 18th, 2011

Amarin Corporation Plc (Nasdaq: AMRN) shares surged 68.5% Monday morning, after it released late-study results yielding positive findings on its medicinal-grade fish oil drug.

The stock added on $6.00 to $14.77, trumping its 52-week peak of $9.66, set early in January. The clinical-stage pharmaceutical, with offices in Dublin and in Mystic, Conn., reported positive, statistically significant top-line results from its ANCHOR trial for the Company’s lead product candidate, AMR101. The Phase 3 trial met its primary and secondary efficacy endpoints for both the 4 gram and 2 gram daily doses.

The purpose of the ANCHOR trial was to demonstrate that AMR101 is effective in reducing triglyceride levels in patients with high triglycerides without increasing LDL-C (“bad cholesterol”) levels in patients on background statin therapy. In the U.S. alone, approximately 40 million people have triglyceride levels above 200 mg/dL. The majority of these patients have high triglyceride levels of ≥200 and <500mg/dL as studied in the ANCHOR trial with approximately 4 million of these people having very triglyceride levels >500 mg/dL as studied in the MARINE trial.

Amarin CEO Joseph S. Zakrzewski, said, “We are delighted by the results of the ANCHOR trial. In November we announced MARINE trial results which position AMR101 to be best-in-class for treating patients with very high triglycerides. The ANCHOR trial results are even more remarkable than the broadly positive MARINE trial results. We believe these results clearly differentiate AMR101 from other triglyceride lowering therapies and position AMR101 to be both first-in-class and best overall therapy for treating the high triglyceride population.”

Amarin reported positive, statistically significant top-line results for both of its two pivotal Phase 3 clinical trials, the MARINE trial (investigation of AMR101 as a treatment for patients with very high triglycerides [>500 mg/dL]), as reported on November 29, 2010 and the ANCHOR trial. The Company is planning to file an non-disclosure agreement (NDA) for AMR101 before the end of Q3 2011.

GTXI gallops, CSCO clicks, NEP slips

Wednesday, April 13th, 2011

GTX Inc. (Nasdaq: GTXI) shares advanced 41.8% to $3.90, on volume of 2.9 million, dwarfing an average of only 85,000, after Citigroup Inc. upgraded the drug company to buy from hold.

Cisco Systems Inc. (Nasdaq: CSCO) traded in 49.2 million shares, making it a volume leader Wednesday, but still falling below its average of 77.5 million. Share prices were down 1.2% to $17.24.

China North East Petroleum (AMEX: NEP) plummeted 15.9% to $3.22, on volume of 2.5 million, towering over a daily average around 440,000.

BIIB big, INTC popular, TDSC bruised

Monday, April 11th, 2011

Biogen Idec Inc. (Nasdaq: BIIB) shares climbed 7% to $78.44. Volume for the stock was 4.9 million, trumping its daily average of 1.8 million, after the biotechnology company said its experimental multiple-sclerosis drug showed promising results in two late-stage studies.

Intel Corp. (Nasdaq: INTC) was a busy company Monday, trading in 31.7 million shares, still short of its daily average of 59.8 million. Share prices for the chips-maker nipped up 0.3% to $20.07, after the company said its new processor for tablets is now available, as it tries to break into the fast-growing mobile market dominated by designs based on rival ARM Holdings PLC’s architecture.

3D Systems Corporation (Nasdaq: TDSC) took a 10.5% tumble in price Monday afternoon to $50.60, on volume of 1.2 million shares, far above its daily average of 247,000.